Holen Sie sich die Stockscreener-App
8.60
1.04%
-0.09
Handel nachbörslich:
8.60
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
Pittsburgh Post-Gazette - FinancialContent
4D Molecular Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You? - Insider Monkey
4D Molecular Therapeutics, Inc.Common Stock (NQ: FDMT - FinancialContent
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
About Us - FinancialContent
User | mammothtimes.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
User | malvern-online.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RA Capital affiliates report 9.99% of 4D Molecular (NASDAQ: FDMT) via warrants and shares - Stock Titan
BVF affiliates report 5.35M 4D shares (FDMT) and 8.48M pre-funded warrants - Stock Titan
Biotech 4D Molecular Therapeutics grants 141,100 RSUs to new employees - Stock Titan
Fat Pitch Financials4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
[EFFECT] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - MSN
FDMT: 4D-150's phase III progress and robust data position it as a potential game-changer in retinal gene therapy - TradingView
State Street (FDMT) discloses 5.3% holdings — 2.7M shares reported on 03/31/2026 - Stock Titan
Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report - simplywall.st
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Analyst Reiterates Buy on 4D Molecular Therapeutics as Wet AMD Gene Therapy Advances, Keeps $36 Price Target Unchanged - TipRanks
4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
4D Molecular Therapeutics, Inc. Stock 12‑Month Price Target Cut to $27.62, Implies 178% Upside - TradingView
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down After Earnings Miss - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) files $400M shelf registration - Stock Titan
Wet AMD gene therapy moves ahead; 4DMT targets 2027 Phase 3 data - Stock Titan
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
[10-Q] 4D Molecular Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
4D Molecular (NASDAQ: FDMT) details Q1 loss and cash runway to 2028 - Stock Titan
4D Molecular Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
4DMT management to present at BofA, RBC healthcare conferences - Stock Titan
4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Thursday - MarketBeat
[ARS] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Board moves key votes at 4D Molecular Therapeutics (NASDAQ: FDMT) 2026 meeting - Stock Titan
FDMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
4D (FDMT) Stock Beneficial Ownership (Grinds Lower) 2026-04-20Real Time Stock Idea Network - Cổng thông tin điện tử tỉnh Lào Cai
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Layoff Watch: What is the Moat Score of 4D Molecular Therapeutics Inc2026 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Janus Henderson (NASDAQ: FDMT) holds 5.25M shares, 10.3% stake in 4D Molecular - Stock Titan
Investment Analysts’ Recent Ratings Changes for 4D Molecular Therapeutics (FDMT) - Defense World
JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Will 4D (FDMT) Stock Hit Record Highs | Price at $9.48, Down 3.95%Crowd Trend Signals - Newser
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Buy Rating from Jefferies Financial Group - Defense World
4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Trade 4D Molecular Therapeutics IncFDMT CFD - Capital.com
4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer - Stock Titan
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $32.71 Consensus Target Price from Analysts - Defense World
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):